Breaking News Bar
posted: 1/30/2013 12:01 AM

FDA warns company over unapproved flu remedy

Success - Article sent! close
Associated Press

WASHINGTON -- Federal regulators say a Florida company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.

The Food and Drug Administration and the Federal Trade Commission issued a warning letter to Flu and Cold Defense LLC for making misleading, unproven claims about its GermBullet inhaler.

Order Reprint Print Article
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The warning comes amid a worse-than-usual flu season that has hit the elderly particularly hard. So far, half of confirmed flu cases are in people 65 and older.

FDA regulators say they are seeing an uptick in bogus flu remedies, including fake flu vaccines, counterfeit antiviral drugs and air filters that allegedly remove the flu from the air.

"When there is a particular health issue in the news fraudulent products spike," said Howard Sklamberg, FDA's director of compliance. "So right now fraud products to prevent or treat the flu are big with scammers."

The Boca Raton, Fla.-based Flu and Cold Defense advertises the product as a "proprietary blend of 11 organic botanicals." The company's website claims that "an FDA recognized virology lab" tested the formula and "confirmed that it has the potential capability to kill cold and flu viruses."

But FDA regulators say the mixture has never been reviewed as safe and effective and the company is violating drug safety regulations.

All new drugs marketed in the U.S. must be submitted for approval to the FDA before they can be sold to consumers. Sklamberg says consumers should remember that "there aren't any legally marketed over-the-counter products to prevent or treat the flu."

The GermBullet is sold online through retailers like and at a handful of small pharmacies and natural food stores in Florida.

A man reached by phone at Flu and Cold Defense's office could not immediately comment on the warning letter.

This year's flu season started about a month earlier than normal and the dominant flu strain is one that tends to make people sicker. The government doesn't keep a running tally of adult deaths from the flu, but estimates that it kills about 24,000 people most years. Vaccinations are recommended for anyone 6 months or older.

Flu and Cold Defense issued a news release early in the month saying GermBullet "may help protect you so your immune system is not overwhelmed as the flu reaches epidemic levels." FDA and FTC regulators take issue with that statement and a number of others from the company's website, including that the inhaler is "shown to reduce illness-causing bacteria, cold and flu viruses and fungi."

The letter, dated Jan. 24, was posted to the FDA's website Tuesday.

Regulators gave the company 15 business days to correct the problematic statements.

"The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence," states the letter.

The FDA regularly issues warning letters to companies that do not follow regulations for manufacturing and promoting drugs and medical devices. The letters are not legally binding, but the FDA can take companies to court if they are ignored.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.